Full-Time
M&S Data Solution Architect
Confirmed live in the last 24 hours
Sanofi
10,001+ employees
Develops pharmaceuticals and vaccines globally
No salary listed
Senior, Expert
Sant Cugat del Vallès, Barcelona, Spain
- Minimum of 8 years of experience in Data Architecture, specializing in relevant technologies such as Snowflake and public cloud services such as AWS and Azure.
- Extensive background in designing, developing, and optimizing data solutions, including data pipelines, architectures, and data sets.
- Excellent written and oral communication skills, with the ability to effectively communicate complex technical concepts to both technical and non-technical stakeholders.
- Experience working with SQL, Relational / NoSQL databases, data query optimization and data warehousing technologies.
- Experience in data governance practices and policies to manage sensitive data effectively.
- Experience in encryption, data masking and data anonymization techniques.
- Proven ability to translate functional requirements into technical/solution design, ensuring alignment with business goals and objectives.
- Experience providing consumer or patient-facing technologies, understanding the unique challenges and requirements of delivering solutions in this space.
- Experience with GxP, HIPAA, and GDPR regulations and the ability to ensure compliance with these regulations in the design and implementation of patient data solutions.
- Strong experience with agile-based development methodologies, with direct experience as a Solution Architect preferred.
- Detail-oriented, customer-driven, and able to work well across time zones on a global team.
- Ability to work collaboratively as a team player, fostering a positive and productive work environment.
- Demonstrated professional and reliable behavior, consistently delivering high-quality work and meeting deadlines.
- Working knowledge of scripting languages (Python, SQL, CLI)
- Bachelor's degree in a relevant field.
- Lead and oversee the design and implementation of all-encompassing solutions for data management in manufacturing and supply. Ensure alignment with architecture strategy and adhere to governance standards.
- Collaborate with business stakeholders, manufacturing experts, and supply chain professionals to understand data requirements and challenges.
- Translate high-level business and functional requirements into data models, metadata and data dictionaries.
- Work closely with data engineers to implement and deploy data pipelines and data integration solutions using Snowflake, Informatica, AWS S3, Python and related technologies.
- Conduct hands-on Proof of Concepts (PoCs) to swiftly verify the feasibility of data solutions and present PoC outcomes to technology and business stakeholders.
- Drive teams of specialized professionals in large-scale programs to successfully deliver projects focused on manufacturing process optimization and quality improvement.
- Streamline and simplify existing data architecture, delivering reusable services and identifying cost-saving opportunities.
- Collaborate with cross-functional teams to ensure complete and operable solutions that align with business processes.
- Optimize data processes to improve efficiency, reduce latency, and enhance overall system performance.
- Provide clear and detailed leadership for manufacturing and supply data architecture within projects.
- Evaluate product usefulness and cost in the supplier selection process.
- Create and maintain current and target-state data architecture roadmaps aligned with business needs.
- Responsible for establishing the strategic direction, choosing technologies, settings standards, and data governance processes for manufacturing and supply services data.
- Evaluate and recommend emerging technologies for data management and analytics.
- Take on the responsibility of safeguarding the integrity and confidentiality of Good Manufacturing Practice (GMP) and Sarbanes-Oxley (SoX) data, ensuring strict adherence to security protocols.
- Stay current with industry trends, best practices, and emerging technologies in Snowflake, data integrations, data management, and related fields.
- Understanding of the life sciences/pharma industry and its specific data architecture requirements.
- Experience with data analytics and visualization platforms like Microsoft PowerBI / Tableau.
- Experience in seamlessly integrating data from SAP systems, ensuring connectivity and interoperability within the organizational framework.
- Experience in integrating data from Internet of Things (IoT) devices.
- Familiarity with pharma industry systems, such as LIMS and MES.
- Familiarity with AI/ML capabilities.
- Familiarity with Source Code Management Tools such as GitHub and Terraform.
Sanofi provides healthcare solutions through the development of treatments and vaccines. The company focuses on research and development to create new therapies for conditions like immunology, oncology, and rare diseases. Their products include prescription medicines, over-the-counter items, and vaccines, which are distributed to patients, healthcare professionals, and governments. Sanofi distinguishes itself from competitors by investing heavily in scientific research and maintaining a strong pipeline of new products, as well as forming strategic partnerships. The company's goal is to enhance health outcomes and improve the quality of life for people globally.
Company Size
10,001+
Company Stage
IPO
Headquarters
Paris, France
Founded
1973
Simplify's Take
What believers are saying
- Sanofi's Q1 2025 profit grew by 20%, driven by Dupixent and new launches.
- The €15M investment in Innate Pharma strengthens Sanofi's oncology pipeline.
- Sanofi's acquisition of Dren Bio for $1.9bn expands its biopharmaceutical capabilities.
What critics are saying
- Increased competition in immunology could impact Dupixent's market share.
- Potential regulatory delays for tolebrutinib may affect market entry and revenue.
- Integration challenges from Dren Bio acquisition could pose financial risks.
What makes Sanofi unique
- Sanofi's acquisition of Vigil Neuroscience enhances its neurology pipeline with Alzheimer's treatment.
- Dupixent's approval for chronic spontaneous urticaria marks a decade-first targeted therapy.
- Tolebrutinib's brain-penetrant mechanism offers a novel approach for multiple sclerosis treatment.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Professional Development Budget
Parental Leave
Company News
Sanofi to acquire Vigil Neuroscience, Inc., adding a new investigational medicine to treat Alzheimer’s disease to the neurology pipeline Paris, May 22, 2025. Sanofi announced today that it has...
Innate Pharma announced a €15M investment by Sanofi, subscribing to 8,345,387 new shares at €1.7974 each. This capital increase supports their ongoing partnership, including the BCMA targeting ANKET® program. The investment will aid in extending Innate's cash runway for pipeline execution. The capital increase is expected to close on April 25, 2025, with shares trading on Euronext Paris the same day.
Dupixent approved in the US as the first new targeted therapy in over a decade for chronic spontaneous urticariaApproval based on phase 3 studies demonstrating Dupixent significantly reduced itch and hives compared to placeboIn the US, there are more than 300,000 adults and adolescents aged 12 years and older living with CSU who remain symptomatic despite antihistamine treatmentCSU is the seventh disease with underlying type 2 inflammation in which Dupixent is approvedParis and Tarrytown, NY, April 18, 2025. The US Food and Drug Administration (FDA) has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1 (H1) antihistamine treatment.Kenneth MendezPresident and Chief Executive Officer at the Asthma and Allergy Foundation of America“People with chronic spontaneous urticaria experience sudden, unpredictable hives and severe itch that cause a significant, and often overwhelming, burden on their everyday lives. The approval of this treatment offers patients more options and the chance to control their disease.”Alyssa Johnsen, M.D., Ph.D.Global Therapeutic Area Head, Immunology and Oncology Development at Sanofi“CSU patients with uncontrolled disease experience highly burdensome itch and hives that can significantly disrupt daily living. This FDA approval provides a new treatment option to help address the underlying drivers of these severe and recurring signs and symptoms. Dupixent has the potential to improve outcomes for CSU patients who previously had limited treatment options.”The US approval is based on data from two phase 3 clinical studies, Study A (n=136) and Study C (n=148), which included biologic-naïve patients aged 12 years and older who were symptomatic despite the use of antihistamines and assessed Dupixent as an add-on therapy to standard-of-care antihistamines, compared to antihistamines alone. Both studies met their primary and key secondary endpoints with Dupixent demonstrating reductions in itch severity and urticaria activity (a composite of itch and hives) compared to placebo at 24 weeks
Sanofi SA (NASDAQ:SNY) reported Thursday a first-quarter 2025 business operating income of 2.9 billion euros ($3.06 billion), up 20.1% year over year and 18.7% in constant currency. The company reported first-quarter sales of 9.89 billion euros ($10.42 billion), beating the consensus of $9.77 billion. This was driven by launches, Dupixent, and favorable Beyfortus phasing. Sales increased 10.8% year over year and 9.7% on constant currency. U.S. sales were 4.66 billion and increased by 15.4%
Results from the HERCULES phase 3 study showed delay in disability progression in people living with non-relapsing secondary progressive multiple sclerosisTolebrutinib has the potential to be the first therapy to modulate immunologic drivers of chronic inflammation behind the blood–brain barrier, a key driver of disability accumulation in MSTolebrutinib is being evaluated under priority review in the US with a target action date of 28 September 2025; regulatory submission dossier is under review in the EU with a decision expected in Q1 2026Paris, April 8, 2025. The New England Journal of Medicine (NEJM) published positive results from the HERCULES phase 3 study demonstrating that tolebrutinib delayed disability progression in people with non-relapsing secondary progressive multiple sclerosis (nrSPMS), where there are currently no treatment options approved. These findings further support the differentiated mechanism of oral, brain-penetrant tolebrutinib, targeting disability progression independent of relapse activity. These results were first presented at the ECTRIMS conference on September 20, 2024 in Copenhagen, Denmark and further analyses were also presented today during the Clinical Trials Plenary Session at the 2025 Annual Meeting for the American Academy of Neurology (AAN) in San Diego, California.Robert Fox, MDVice Chair of Research at Cleveland Clinic’s Neurological Institute, Cleveland, Ohio, US, and chair of the HERCULES global steering committee“Tolebrutinib represents a new class of therapy for the treatment of multiple sclerosis. In this large phase 3 study, tolebrutinib was found to slow the progression of disability in a subset of multiple sclerosis for which we have no approved therapies – non-relapsing secondary progressive disease. The results of this study signal a new chapter in multiple sclerosis because we finally found a potential way to treat non-relapsing secondary progressive forms.”Dr Fox is a paid advisor to Sanofi for the HERCULES study.Erik Wallström, MD, PhDGlobal Head of Neurology Development“By targeting disability progression mechanisms behind the blood-brain barrier, tolebrutinib has the potential to be a practice-changing therapeutic option for people living with multiple sclerosis